Literature DB >> 15565640

Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong.

K Y Leung1, C P Lee, M H Y Tang, E T Lau, L K L Ng, Y P Lee, H Y Chan, E S K Ma, Vivian Chan.   

Abstract

OBJECTIVES: To determine the cost effectiveness of a universal prenatal screening program for alpha- and beta-thalassaemia.
METHODS: We retrospectively reviewed our program from 1998 to 2002, and calculated the direct and indirect costs of various components.
RESULTS: 18,936 women were screened at our prenatal clinic and 153 couples were subsequently referred to our Prenatal Diagnostic Centre for counselling and further investigations. In addition, there were 238 tertiary referrals and 157 self-referrals. After investigations, 84 fetuses were at risk of beta-thalassaemia major/beta-E thalassaemia, 19 of them were affected and 18 were aborted. The total expenditure on our program (HK 10.0 million dollars) would be less than the postnatal service costs (HK 40.4 million dollars) for 18beta-thalassaemia major fetuses if they were born. Of 361 women at risk of carrying a homozygous alpha0-thalassaemia fetus, 311 (86.2%) opted for the indirect approach (using serial ultrasound examinations to exclude Hb Bart's disease), and 76 (24.5%) subsequently underwent an invasive test for a definitive diagnosis. The sensitivity and false positive rate of this indirect approach was 100.0% and 2.9% respectively.
CONCLUSION: It is cost effective to run a universal prenatal screening program in an area where both beta-thalassaemia and alpha-thalassaemia are prevalent. The indirect approach can effectively avoid an invasive test in unaffected pregnancies. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15565640     DOI: 10.1002/pd.1035

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  6 in total

1.  Screening and counseling for thalassemia.

Authors:  David H K Chui; Melody J Cunningham; Hong-Yuan Luo; Lawrence C Wolfe; Ellis J Neufeld; Martin H Steinberg
Journal:  Blood       Date:  2006-02-15       Impact factor: 22.113

Review 2.  An international registry of survivors with Hb Bart's hydrops fetalis syndrome.

Authors:  Duantida Songdej; Christian Babbs; Douglas R Higgs
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

3.  Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India.

Authors:  Nishi Madan; Satendra Sharma; S K Sood; Roshan Colah; Late H M Bhatia
Journal:  Indian J Hum Genet       Date:  2010-01

4.  Comprehensive analysis of recessive carrier status using exome and genome sequencing data in 1543 Southern Chinese.

Authors:  Jeffrey Fong Ting Chau; Mullin Ho Chung Yu; Martin Man Chun Chui; Cyrus Chun Wing Yeung; Aaron Wing Cheung Kwok; Xuehan Zhuang; Ryan Lee; Jasmine Lee Fong Fung; Mianne Lee; Christopher Chun Yu Mak; Nicole Ying Ting Ng; Claudia Ching Yan Chung; Marcus Chun Yin Chan; Mandy Ho Yin Tsang; Joshua Chun Ki Chan; Kelvin Yuen Kwong Chan; Anita Sik Yau Kan; Patrick Ho Yu Chung; Wanling Yang; So Lun Lee; Godfrey Chi Fung Chan; Paul Kwong Hang Tam; Yu Lung Lau; Kit San Yeung; Brian Hon Yin Chung; Clara Sze Man Tang
Journal:  NPJ Genom Med       Date:  2022-03-21       Impact factor: 8.617

5.  Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of iran.

Authors:  Elham Ahmadnezhad; Nariman Sepehrvand; Farshid Fayyaz Jahani; Sanaz Hatami; Catauon Kargar; Majid Mirmohammadkhani; Shahrzad Bazargan-Hejazi
Journal:  Int J Prev Med       Date:  2012-10

6.  Clinical Implementation of Expanded Carrier Screening in Pregnant Women at Early Gestational Weeks: A Chinese Cohort Study.

Authors:  Mengmeng Shi; Angeline Linna Liauw; Steve Tong; Yu Zheng; Tak Yeung Leung; Shuk Ching Chong; Ye Cao; Tze Kin Lau; Kwong Wai Choy; Jacqueline P W Chung
Journal:  Genes (Basel)       Date:  2021-03-29       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.